PL1750703T3 - Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru - Google Patents

Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru

Info

Publication number: PL1750703T3
Authority: PL; Poland
Prior art keywords: tegafur; gastrointestinal toxicity; administration; toxicity due; reducing gastrointestinal
Prior art date: 2004-04-29

Application number

PL05738545T

Other languages

English (en)

Inventor

Takeshi Tahara

Hiroshi Ambe

Jun Kuritani

Naruo Nomura

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-29

Filing date

2005-04-27

Publication date

2012-05-31

2005-04-27 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2012-05-31 Publication of PL1750703T3 publication Critical patent/PL1750703T3/pl

Links

WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title abstract 3
229960001674 tegafur Drugs 0.000 title abstract 3
206010059024 Gastrointestinal toxicity Diseases 0.000 title abstract 2
231100000414 gastrointestinal toxicity Toxicity 0.000 title abstract 2
RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
235000020937 fasting conditions Nutrition 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
229950000193 oteracil Drugs 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

PL05738545T 2004-04-29 2005-04-27 Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru PL1750703T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US56618004P	2004-04-29	2004-04-29
EP05738545A EP1750703B1 (en)	2004-04-29	2005-04-27	Method for reducing gastrointestinal toxicity due to the administration of tegafur
PCT/JP2005/008450 WO2005105086A1 (en)	2004-04-29	2005-04-27	Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (1)

Publication Number	Publication Date
PL1750703T3 true PL1750703T3 (pl)	2012-05-31

Family

ID=35241420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05738545T PL1750703T3 (pl)	2004-04-29	2005-04-27	Sposób obniżania toksyczności żołądkowo-jelitowej powodowanej podawaniem tegafuru

Country Status (16)

Country	Link
US (1)	US20080166427A1 (pl)
EP (1)	EP1750703B1 (pl)
JP (1)	JP5376758B2 (pl)
AT (1)	ATE540679T1 (pl)
AU (1)	AU2005237364B2 (pl)
CY (2)	CY1112451T1 (pl)
DK (1)	DK1750703T3 (pl)
ES (1)	ES2378072T3 (pl)
HR (1)	HRP20120293T1 (pl)
ME (1)	ME01335B (pl)
PL (1)	PL1750703T3 (pl)
PT (1)	PT1750703E (pl)
RS (1)	RS52217B (pl)
RU (1)	RU2348409C2 (pl)
SI (1)	SI1750703T1 (pl)
WO (1)	WO2005105086A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010131769A1 (en) *	2009-05-13	2010-11-18	Taiho Pharmaceutical Co., Ltd.	Treatment of diffuse-type gastric cancers using s-1 and cisplatin
CN102648412A (zh) *	2009-07-17	2012-08-22	美瑞德生物工程公司	5-fu的检测方法
WO2011022174A1 (en) *	2009-08-21	2011-02-24	Myriad Genetics, Inc.	Method of processing blood samples containing 5-fu
EP2422784A1 (en)	2010-08-18	2012-02-29	Grindeks, a joint stock company	Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422848A1 (en)	2010-08-18	2012-02-29	Grindeks, a joint stock company	Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422815A1 (en)	2010-08-18	2012-02-29	Grindeks, a joint stock company	Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
US10172839B2 (en)	2014-03-06	2019-01-08	University Of Southern California	Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
WO2015134837A2 (en) *	2014-03-06	2015-09-11	University Of Southern California	Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944088C (en) *	2014-03-28	2022-06-21	L-Nutra Inc.	Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
EP3290038A4 (en) *	2015-04-30	2018-12-26	Taiho Pharmaceutical Co., Ltd.	Agent for alleviating adverse reaction to antitumor drug
JP6439761B2 (ja) *	2016-08-09	2018-12-19	トヨタ自動車株式会社	ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) *	2016-12-30	2018-05-01	陈晓华	一种用于治疗癌症的药物组合物、试剂盒及其应用
US20250186435A1 (en) *	2020-05-19	2025-06-12	Cellix Bio Private Limited	Pharmaceutical formulations and their preparations for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3635946A (en) *	1969-07-22	1972-01-18	Solomon Aronovich Giller	N1-(2'-furanidyl)-derivatives of 5-substituted uracils
EP0180188B1 (en) *	1984-10-30	1992-04-15	Otsuka Pharmaceutical Co., Ltd.	A composition for increasing the anti-cancer activity of an anti-cancer compound
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
NL194430C (nl) *	1989-01-05	2002-04-04	Otsuka Pharma Co Ltd	Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
WO1992021345A1 (en) *	1991-05-27	1992-12-10	Taiho Pharmaceutical Co., Ltd.	Composition, method and kit for potentiating antitumor activity and for curing tumor
RU2198171C2 (ru) *	1998-10-12	2003-02-10	Леонидов Николай Борисович	Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием

2005
- 2005-04-27 ME MEP-2012-42A patent/ME01335B/me unknown
- 2005-04-27 ES ES05738545T patent/ES2378072T3/es not_active Expired - Lifetime
- 2005-04-27 SI SI200531451T patent/SI1750703T1/sl unknown
- 2005-04-27 AT AT05738545T patent/ATE540679T1/de active
- 2005-04-27 US US11/587,643 patent/US20080166427A1/en not_active Abandoned
- 2005-04-27 RS RS20120127A patent/RS52217B/sr unknown
- 2005-04-27 DK DK05738545.2T patent/DK1750703T3/da active
- 2005-04-27 PT PT05738545T patent/PT1750703E/pt unknown
- 2005-04-27 HR HR20120293T patent/HRP20120293T1/hr unknown
- 2005-04-27 AU AU2005237364A patent/AU2005237364B2/en not_active Ceased
- 2005-04-27 JP JP2006539166A patent/JP5376758B2/ja not_active Expired - Fee Related
- 2005-04-27 WO PCT/JP2005/008450 patent/WO2005105086A1/en not_active Ceased
- 2005-04-27 EP EP05738545A patent/EP1750703B1/en not_active Expired - Lifetime
- 2005-04-27 PL PL05738545T patent/PL1750703T3/pl unknown
- 2005-04-27 RU RU2006142101/14A patent/RU2348409C2/ru active
2012
- 2012-03-07 CY CY20121100222T patent/CY1112451T1/el unknown
- 2012-05-31 CY CY2012014C patent/CY2012014I2/el unknown

Also Published As

Publication number	Publication date
ATE540679T1 (de)	2012-01-15
DK1750703T3 (da)	2012-05-07
RS52217B (sr)	2012-10-31
ME01335B (me)	2013-12-20
SI1750703T1 (sl)	2012-02-29
AU2005237364A1 (en)	2005-11-10
EP1750703B1 (en)	2012-01-11
CY2012014I1 (el)	2016-04-13
AU2005237364B2 (en)	2010-07-08
US20080166427A1 (en)	2008-07-10
RU2348409C2 (ru)	2009-03-10
CY1112451T1 (el)	2015-12-09
EP1750703A1 (en)	2007-02-14
HRP20120293T1 (hr)	2012-04-30
WO2005105086A1 (en)	2005-11-10
JP2007534634A (ja)	2007-11-29
JP5376758B2 (ja)	2013-12-25
ES2378072T3 (es)	2012-04-04
PT1750703E (pt)	2012-02-23
CY2012014I2 (el)	2016-04-13
EP1750703A4 (en)	2008-02-27
RU2006142101A (ru)	2008-06-20

Publication	Publication Date	Title
TW200833370A (en)	2008-08-16	Pharmaceutical composition containing low substituted hydroxypropylcellulose
PL369108A1 (pl)	2005-04-18	Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu
WO2007138472A3 (en)	2008-02-07	Triazolopyridazine derivatives
WO2006011050A3 (en)	2006-10-05	Pyridine derivatives
SG147450A1 (en)	2008-11-28	Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
UA96449C2 (en)	2011-11-10	Stable laquinimod preparations
TW200621737A (en)	2006-07-01	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ZA200806778B (en)	2009-11-25	N-Hydroxyacrylamide compounds
CY1112451T1 (el)	2015-12-09	Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
MXPA06009475A (es)	2007-05-15	Derivados de quinazolina y usos terapeuticos de los mismos.
ZA200603538B (en)	2007-09-26	P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
WO2006116148A3 (en)	2008-09-12	(7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
MX2007004740A (es)	2007-06-18	Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica.
MXPA05006889A (es)	2006-04-07	Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
TNSN08369A1 (en)	2009-12-29	Benzimidazole derivatives
MX2009007038A (es)	2009-08-25	Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
TNSN06220A1 (en)	2007-12-03	Benzimidazole derivatives
WO2006072000A3 (en)	2008-12-24	Xanthurenic acid derivative pharmaceutical compositoins and methods related thereto
MX2009005242A (es)	2009-08-19	Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
WO2004048381A3 (en)	2004-08-05	Pyrazoloazepine compounds as pharmaceutical agents
MXPA05007253A (es)	2005-12-14	Sales novedosas de derivados anticonvulsivantes.
WO2007001839A3 (en)	2007-04-26	4-anilino-3-quinolinecarbonitriles for the treatment of cancer
WO2005097757A3 (en)	2005-12-08	Nucleoside derivatives and therapeutic use thereof
WO2006004903A3 (en)	2006-05-04	1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
TW200633701A (en)	2006-10-01	Thioether derivatives, their manufacture and use as pharmaceutical agents